FDA 483 - Lonza AG - April 04, 2025

An FDA inspection of Lonza AG in Visp, Switzerland, revealed deficiencies in procedures designed to prevent microbiological contamination of sterile drug products. Operators were observed covering sterile openings and blocking first air during aseptic assembly and stopper addition operations. These findings indicate a failure to establish and follow adequate controls for sterile manufacturing.